| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 05/07/2002 | US6384086 Administering to host effective amount of storage stable ethene for improving metabolic function |
| 05/07/2002 | US6384083 Controlling viruses of bornaviridae family by administering adamantane amines to human and animals at therapeutically effective dosage by means selected from oral, parenteral, intramuscular, subcutaneous, intradermal and topical |
| 05/07/2002 | US6384074 Activating cell growth in human by applying specified plant extract to skin |
| 05/07/2002 | US6384064 Human immunodeficiency syndrone, hepatitis virus |
| 05/07/2002 | US6384036 Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors |
| 05/07/2002 | US6384030 Water soluble azoles as broad-spectrum antifungals |
| 05/07/2002 | US6384019 Gemcitabine derivatives |
| 05/07/2002 | US6384018 For inducing immune responses in a vertebrate against mycobacterial epitopes |
| 05/07/2002 | US6384014 Antibiotics as bactericides |
| 05/07/2002 | US6383785 Self-enhancing, pharmacologically controllable expression systems |
| 05/07/2002 | US6383780 2786, a novel human aminopeptidase |
| 05/07/2002 | US6383768 Method for producing in vitro the RNA-dependent RNA polymerase and terminal nucleotidyl transferase activities encoded by hepatitis C virus (HCV) |
| 05/07/2002 | US6383741 Administering an attenuation virus |
| 05/07/2002 | US6383739 Drug screening by isolating blood cells then cd8+ cells from donors, culturing with compound for 3 days, culturing in with interleukin-2, detecting immunodeficiency-virus suppressing lymphokine expression, then further analysis |
| 05/07/2002 | US6383738 Herpes simplex virus ORF P is a repressor of viral protein synthesis |
| 05/07/2002 | US6383496 Recombinant vaccines comprising immunogenic attenuated bacteria having RPOS positive phenotype |
| 05/07/2002 | US6383488 Pre-M/M epitopes of dengue virus, synthetic peptides, chimeric proteins and their use |
| 05/07/2002 | US6383487 Antitumor |
| 05/07/2002 | CA2223700C In ovo vaccination against coccidiosis |
| 05/07/2002 | CA2214884C Poly(hydroxy acid)/polymer conjugates for skin applications |
| 05/07/2002 | CA2175842C Transesterified corn oil products |
| 05/02/2002 | WO2002035242A1 Method for identifying novel molecules binding with lox receptor |
| 05/02/2002 | WO2002035236A1 Method for identifying novel molecules binding with the scavenger receptors and signalled via a toll receptor |
| 05/02/2002 | WO2002035235A2 Net as regulator of angiogenic expression |
| 05/02/2002 | WO2002034789A1 Monoclonal antibodies directed against hepatitis b viruses |
| 05/02/2002 | WO2002034788A1 Monoclonal antibodies to the map protein and method of use in treating or preventing infections |
| 05/02/2002 | WO2002034783A2 Transmembrane proteins |
| 05/02/2002 | WO2002034769A2 Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150 |
| 05/02/2002 | WO2002034753A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034752A1 Antifungal 4-substituted 5,6-dihydro-4h-pyrrolo[1,2-a][1,4]benzodiazepines |
| 05/02/2002 | WO2002034750A1 Process for formulation of antibiotic compounds |
| 05/02/2002 | WO2002034747A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 05/02/2002 | WO2002034745A1 Chemokine receptor binding heterocyclic compounds |
| 05/02/2002 | WO2002034726A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034721A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/02/2002 | WO2002034718A1 Amide derivatives as nmda receptor antagonists |
| 05/02/2002 | WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | WO2002034705A2 C-nitroso compounds and use thereof |
| 05/02/2002 | WO2002034303A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | WO2002034293A2 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent |
| 05/02/2002 | WO2002034284A2 Methods of therapy for hiv infection |
| 05/02/2002 | WO2002034239A1 Use of hydrophilic particles associated with antigens for preparing vaccine compositions |
| 05/02/2002 | WO2002034221A1 Dental care compositions |
| 05/02/2002 | WO2002034203A2 Novel derivatives of phenyl 4-aminosalicylate and method of making the same |
| 05/02/2002 | WO2002034202A2 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | WO2002034119A2 Vaccine immunotherapy for immune suppressed patients |
| 05/02/2002 | WO2002022080A3 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| 05/02/2002 | WO2002012537A3 Mutant trichosanthin |
| 05/02/2002 | WO2002011710A3 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 05/02/2002 | WO2002011677A3 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 05/02/2002 | WO2002006460A3 Masp-2, a complement-fixing enzyme, and uses for it |
| 05/02/2002 | WO2002002121A3 Method for treatment and prevention of mastitis |
| 05/02/2002 | WO2001098330A3 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 05/02/2002 | WO2001096397A3 Cd154 variants and uses thereof |
| 05/02/2002 | WO2001096368A3 Use of coiled-coil structural scaffold to generate structure-specific peptides |
| 05/02/2002 | WO2001096283A3 Hiv integrase inhibitors |
| 05/02/2002 | WO2001092311A3 Convergent combinatory peptide libraries and their use for vaccination against hepatitis c virus |
| 05/02/2002 | WO2001092282A3 Methods and compositions for treating flaviviruses and pestiviruses |
| 05/02/2002 | WO2001091803A3 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 05/02/2002 | WO2001090121A3 Methods and compositions for treating hepatitis c virus |
| 05/02/2002 | WO2001090074A3 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 05/02/2002 | WO2001077137A9 Albumin fusion proteins |
| 05/02/2002 | WO2001072778A3 Method of identifying inhibitors of tie-2 |
| 05/02/2002 | WO2001070951A3 Agent for the diagnosis and therapy of viral diseases |
| 05/02/2002 | WO2001064749A3 Method for preparing anti-mif antibodies |
| 05/02/2002 | WO2001062923A3 Transporters and ion channels |
| 05/02/2002 | WO2001062289A3 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 05/02/2002 | WO2001060162A3 Cationic, amphipathic beta-sheet peptides and uses thereof |
| 05/02/2002 | WO2001052667A3 Pet food composition for treating helicobacter species in pets |
| 05/02/2002 | WO2001048209A3 Genes identified as required for proliferation of e. coli |
| 05/02/2002 | WO2001046394A3 Mammalian protein phosphatases |
| 05/02/2002 | WO2001045667A3 Water-soluble powders for oral solution and use thereof |
| 05/02/2002 | WO2001044264A3 Novel stromelysin inhibitors |
| 05/02/2002 | WO2001042308A3 Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1 |
| 05/02/2002 | WO2001034767A3 22 human secreted proteins |
| 05/02/2002 | WO2001032181A3 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum |
| 05/02/2002 | WO2001029070A3 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 05/02/2002 | WO2001023375A3 Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| 05/02/2002 | WO2001009121A3 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 05/02/2002 | WO2001008671A3 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 05/02/2002 | WO2001007651A3 Transposon mediated differential hybridisation |
| 05/02/2002 | WO1999058683A9 BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM $i(NEISSERIA MENINGITIDIS) |
| 05/02/2002 | US20020052513 Oxamide IMPDH inhibitors |
| 05/02/2002 | US20020052507 Process for making 3-amino-2-chloro-4-methylpyridine |
| 05/02/2002 | US20020052481 Non-peptidyl moiety-conjugated CD4-gamma2 and CD4 -IgG2 immunoconjugates, and uses thereof |
| 05/02/2002 | US20020052469 Amino acid sequences for use in detection and treatment of viral infection |
| 05/02/2002 | US20020052443 Non-antigenic branched polymer conjugates |
| 05/02/2002 | US20020052419 Ophthalmic compositions for soft contact lens, method of enhancing wettability of soft contact lens and method of inhibiting terpenoid adsorption |
| 05/02/2002 | US20020052404 Compositions and methods for treating or preventing diseases of body passageways |
| 05/02/2002 | US20020052398 Pharmaceutical composition of 6-amino EM-12 |
| 05/02/2002 | US20020052390 Treating non-invasive fungus-induced otitis media by mucoadministering an antifungal agent. |
| 05/02/2002 | US20020052386 Pyrimidine derivatives |
| 05/02/2002 | US20020052381 Method of using diketopiperazines and composition containing them |
| 05/02/2002 | US20020052379 Highly homogeneous form; stable pharmaceutical dosage forms, including an aqueous suspension |
| 05/02/2002 | US20020052363 Piperazine- or diazepine-containing compounds; useful in the treatment of cancer. |
| 05/02/2002 | US20020052352 Treating a malignant tumor, like a melanoma, using plant-derived compounds |
| 05/02/2002 | US20020052337 Composition and method for inhibiting platelet aggregation |
| 05/02/2002 | US20020052328 Useful as antibacterial and antiprotozoal agents in mammals, including man, as well as in fish and birds. |
| 05/02/2002 | US20020052323 Protease inhibitors, particularly for caspase enzyme; treating arthritis, ALS, MS, and the like. |
| 05/02/2002 | US20020052317 Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |